Refined ELN 2024 risk stratification improves survival prognostication after venetoclax-based therapy in AML,Blood

当前位置： X-MOL 学术 › Blood › 论文详情

Our official English website, www.x-mol.net, welcomes your feedback! (Note: you will need to create a separate account there.)

Refined ELN 2024 risk stratification improves survival prognostication after venetoclax-based therapy in AML
Blood ( IF 21.0 ) Pub Date : 2024-11-04 , DOI: 10.1182/blood.2024026925
Curtis Lachowiez, Vishvaas Ravikumar, Jad Othman, Jenny O’Nions, Daniel Peters, Christine McMahon, Ronan Swords, Rachel Cook, Jennifer Saultz, Jeffrey Tyner, Richard Dillon, Joshua F. Zeidner, Daniel A. Pollyea

The European LeukemiaNet 2024 risk-stratification guidelines for patients with acute myeloid leukemia receiving hypomethylating agents combined with venetoclax were recently published. This analysis demonstrates reclassification and incorporation of new gene mutations in the present model can further improve and individualize prognostication.

中文翻译：